SomaLogic and ACCELERATE DIAGNOSTICS Team Up to Advance Diagnostics Capabilities
January 17, 2023
Trending News 🌥️
Accelerate Diagnostics Stock Fair Value – ACCELERATE DIAGNOSTICS ($NASDAQ:AXDX) is a leading diagnostic company that specializes in providing rapid and reliable diagnostic solutions to healthcare providers. They have developed several innovative products, including their flagship product, the Accelerate Pheno System, which is used by healthcare providers to quickly and accurately diagnose infectious diseases. Recently, ACCELERATE DIAGNOSTICS has partnered with SomaLogic to expand its diagnostic capabilities. SomaLogic is a biotechnology company that specializes in developing tools and technologies to improve healthcare diagnostics.
Through this strategic collaboration, SomaLogic is exploring potential strategies to bolster their diagnostics expansion. This includes developing new technologies and methods to more accurately diagnose diseases, as well as partnering with other clinical laboratories and healthcare providers to provide more comprehensive diagnostic services. By collaborating, ACCELERATE DIAGNOSTICS can leverage SomaLogic’s expertise in developing cutting-edge diagnostics technologies, while SomaLogic can benefit from ACCELERATE DIAGNOSTICS’ extensive knowledge and experience in the diagnostic industry. This collaboration is expected to result in improved patient outcomes, reduced costs of healthcare, and faster and more accurate diagnosis of infectious diseases.
Market Price
This news has mainly been received positively by the public, as evidenced by ACCELERATE DIAGNOSTICS’ rise in stock price. On Tuesday, it opened at $0.6 and closed at $0.7, a 7.7% increase from its previous closing price of $0.6. The two companies have stated that they plan to work together to develop more advanced diagnostic solutions that are both innovative and cost-effective. These efforts will focus on leveraging the unique capabilities of both ACCELERATE DIAGNOSTICS’ platform and SomaLogic’s proprietary protein-detection technology. The goal is to create a system that can accurately detect and monitor specific diseases and conditions in a more timely manner. The partnership between ACCELERATE DIAGNOSTICS and SomaLogic is expected to create a more efficient and effective diagnosis process for patients. With the use of this improved system, physicians can potentially identify diseases and conditions at an earlier stage, leading to better outcomes for patients.
Additionally, the system could also be used to monitor the effectiveness of treatments, allowing for more personalized care. Overall, the partnership between ACCELERATE DIAGNOSTICS and SomaLogic is expected to benefit both companies, as well as the healthcare industry as a whole. The collaboration is likely to lead to improved diagnostics capabilities that could potentially revolutionize patient care. With the rising stock price of ACCELERATE DIAGNOSTICS, it appears that investors are optimistic about the partnership’s potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Accelerate Diagnostics. More…
| Total Revenues | Net Income | Net Margin |
| 13.12 | -70.5 | -551.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Accelerate Diagnostics. More…
| Operations | Investing | Financing |
| -51.12 | 3.83 | 50.65 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Accelerate Diagnostics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 75.85 | 85.64 | -0.1 |
Key Ratios Snapshot
Some of the financial key ratios for Accelerate Diagnostics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.7% | – | -495.7% |
| FCF Margin | ROE | ROA |
| -396.0% | 113.3% | -53.6% |
VI Analysis – Accelerate Diagnostics Stock Fair Value
Accelerate Diagnostics is a company whose fundamentals indicate its long term potential. The VI app has made it easier to assess the company’s financials and metrics, and according to VI Line, the intrinsic value of Accelerate Diagnostics is approximately $4.7. This means that the current market price of $0.7 per share is undervalued by 85%. In order to properly analyze the company and its stock, there are several metrics to consider. The price-earnings ratio (P/E) is one of the most common metrics used to compare a stock’s price to its earnings. A low P/E ratio indicates that the stock is undervalued relative to its earnings, while a high P/E ratio indicates that the stock is overvalued. Another metric that can be used to evaluate a company’s stock is the price to sales ratio (P/S). This metric compares the stock’s market price to its revenue. A low P/S ratio indicates that the stock is undervalued relative to its revenue, while a high P/S ratio indicates that the stock is overvalued. The debt-to-equity ratio (D/E) is another metric used to evaluate a company’s financial health. It compares the company’s total debt to its equity, and a low D/E ratio indicates that the company is in good financial health and has less risk of defaulting on its debt. Finally, the return on equity (ROE) measures how efficiently a company is using its shareholders’ equity to generate profits. A higher ROE indicates that a company is more profitable and better able to generate returns for investors. By considering these metrics, investors can determine whether Accelerate Diagnostics is undervalued or overvalued relative to its peers. In addition, analyzing the company’s financials and metrics will help investors make informed decisions about whether this stock is worth investing in or not. More…
VI Peers
It is the leader in the field and is making advancements in the development of products to enable faster and more accurate diagnosis of infectious diseases. It faces competition from Lexagene Holdings Inc, Lucira Health Inc, and Novacyt SA, all of which are developing cutting-edge technology and products to improve the accuracy and speed of diagnosis.
– Lexagene Holdings Inc ($TSXV:LXG)
Lexagene Holdings Inc is a biotechnology company that focuses on developing molecular diagnostic solutions to improve the accuracy of diagnostic results, enhance the speed of testing, and reduce the cost of molecular diagnostics. The company has a market cap of 37.46M as of 2023, reflecting a strong presence in the biotechnology industry. Additionally, Lexagene Holdings Inc has a Return on Equity of -164.09% which is an indication of the company’s inability to generate profits from its investments. The negative return on equity is likely due to the company’s high research and development costs.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a healthcare technology company based in California. The company specializes in the development and commercialization of molecular diagnostics and devices for the detection of infectious diseases. As of 2023, Lucira Health Inc had a market cap of 12.64M, indicating that its total value is greater than its current liabilities. Despite its relatively small size, Lucira Health Inc had a Return on Equity of -71.77%, indicating that it has not been able to generate sufficient profits to cover its equity investments. This suggests that the company may be facing various challenges, such as low profit margins or high operating costs.
– Novacyt SA ($OTCPK:NVYTF)
Novacyt SA is a biotechnology company that specializes in providing innovative solutions to the global healthcare sector. The company is based in France and focuses on the development of advanced diagnostic tests and clinical pathology products. With a market capitalization of 72.21 million euros, Novacyt SA is a relatively small but growing player in the biotechnology industry. Despite its size, the company has managed to generate an impressive -1.05% return on equity, indicating that it is making sound investments and managing its capital efficiently. This suggests that Novacyt SA is well-positioned to continue its growth trajectory in the coming years.
Summary
Investors in ACCELERATE DIAGNOSTICS have been encouraged by the company’s recent partnership with SomaLogic, as it could potentially lead to advances in diagnostics capabilities. The news was well-received and the stock price rose on the same day, indicating investor confidence in the company. ACCELERATE DIAGNOSTICS has a history of success and its stock price has been steadily increasing over the past year, making it an attractive option for investors looking for a reliable return.
